Editing Ai Clinical Trials (section)

== <span style="color: #FFFFFF;">Understanding</span> ==
Clinical trials fail for many reasons — the drug doesn't work, the wrong patients are enrolled, the trial is too small, patients drop out, or the primary endpoint isn't sensitive enough. AI addresses each failure mode.

'''Patient recruitment''': 80% of trials fail to recruit on time; 50% are delayed by recruitment. ML models applied to EHR data identify eligible patients by automatically parsing complex eligibility criteria against structured and unstructured patient records. NLP converts free-text inclusion/exclusion criteria into machine-executable queries. Trinetx and Veeva AI demonstrate 50–70% reduction in recruitment timelines in pilot studies.

'''Adaptive trial design''': Traditional trials have fixed sample sizes and endpoints. Adaptive designs allow pre-specified modifications: stopping early for efficacy or futility, dropping non-performing arms, changing sample size based on interim analyses. ML and Bayesian statistics enable more complex adaptation rules. The I-SPY2 trial (breast cancer) uses adaptive design to screen multiple drugs simultaneously, graduating effective drugs to Phase III at higher rates than traditional Phase II.

'''Synthetic control arms''': When historical data is available for the standard of care, ML (propensity score matching, Bayesian hierarchical models) constructs a "synthetic control" from historical patients, reducing the number of patients needed in the control arm — making trials faster and more ethical (fewer patients receive placebo).

'''Safety signal detection''': Traditional adverse event analysis looks at aggregate rates post-trial. ML can detect subtle safety signals — patterns of adverse events across patients that no individual event suggests — in real time during the trial. This enables earlier stopping for harm and faster reporting to regulators.
</div>

<div style="background-color: #8B0000; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">